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Clinical Predictors of Response to Depression Treatment in Persons with Epilepsy 




The literature on predictors of response to treatment of depression for persons with epilepsy is 
limited. This study examined predictors of response to treatment of major depression disorder 
(MDD) by cognitive behavioral therapy (CBT) or Sertraline in Epilepsy patients.  
Methods: 
In the original two-site comparative effectiveness trial, 140 adult outpatients with active epilepsy 
and current major depressive disorder were randomly assigned to either sertraline (at a dose 
starting at 50 mg per day, titrating as needed at two-week intervals up to 200 mg per day) or 
weekly cognitive behavior therapy (CBT) for 16 weeks1.  The primary outcome measure was the 
depression module of the MINI-International Neuropsychiatric Interview (M.I.N.I.).  Secondary 
outcomes included the Quality of Life in Epilepsy Inventory (QOLIE)-89, seizure rates, the 
Adverse Events Profile (AEP), the Beck Depression Inventory II, and the M.I.N.I. Suicide Risk 
Module. A logistic regression model analysis was performed on patient clinical, psychosocial, 
and demographic variables previously identified as significantly significant in an attempt to 
develop a predictive model for positive MDD treatment response in persons with Epilepsy.  
Results:  
The variable that was predictive of MDD treatment response was the severity of the depression 
at baseline according to the Centers for Epidemiological Studies- Depression (CES-D) with a 
more severe baseline depression showing a lower response rate.  
Conclusion: 
The more severe MDD at baseline in epilepsy patients was shown to be predictive of a lower 
response to depression treatment with Sertraline or CBT in persons with Epilepsy.  
 
Introduction: 
The clinical usefulness of predictors of response to treatment is obvious. Several studies have 
investigated the clinical predictors of response to acute treatment of major depressive disorder2. 
There is no literature on the predictors of response to MDD treatment in persons with Epilepsy. 
Epilepsy affects over 1% of the US population3. Depression is the most common comorbid 
disorder in epilepsy, and is associated with reduced quality of life, increased health-care 
utilization, and greater mortality4-7.  A recent population-based study found that suicide is 
increased 32-fold in persons with a history of both epilepsy and affective disorder compared to 
the general population 8.  
A randomized control trial of Sertraline and Cognitive Behavioral Therapy was done for persons 
with Epilepsy and MDD.  Depression improved following sertraline or CBT, with most subjects 
in both groups achieving remission.  Despite the complex psychosocial disability associated with 
recurrent seizures, improving depression can have a substantial benefit to quality of life.  This 
study examines predictors of response to depression treatment with persons with epilepsy. The 
data comes from the RCT trial of Sertraline and CBT for depression in Epilepsy, two-site 
comparative effectiveness trial1.  
Material and Methods: 
In the original study, a 16-week intervention intended to eliminate depression was administered. 
The study randomly assigned 140 adult outpatients with epilepsy and current major depressive 
disorder to sertraline or weekly CBT for 16 weeks. Each subject’s physician continued epilepsy 
management. Either sertraline or CBT was the treatment for depression. Sertraline was initiated 
at 50mg per day and increased by 50mg at 2-week intervals as needed for a CES-D score > 14, 
up to a maximum dose of 200 mg per day. Cognitive behavior therapy was administered by a 
licensed therapist using standardized, manual-based Beck guidelines in a 1-hour session each 
week. The therapist completed a weekly written assessment to document the components of CBT 
utilized in each session. Participants were encouraged to attend every session in person, but a 
minority of the sessions could be performed by telephone in consideration of transportation 
limitations of many persons with epilepsy. If subjects stopped assigned treatment but did not 
withdraw consent to participate, the protocol allowed outcomes assessments to be continued for 
the entire 16-week study period. 
Baseline assessments were made prior to randomization. Subjects were re-evaluated with each 
outcome measure during a research clinic visit every 4 weeks. A telephone assessment for 
depression severity (Beck Depression Inventory [BDI] and CES-D), seizures, and treatment side 
effects was obtained at the 2-week interval between clinic visits.  A detailed description of the 
rationale and design of the overall project may be found in Gilliam FG et al1. 
 
The statistical analysis of the data was carried out with the statistical package SPSS Version 27 
in two steps.  Variables were selected for inclusion of the analysis based on their known 
association with depression and were assessed at baseline. These included gender, age, years of 
education, baseline depression severity scores (CES-D), baseline QILIE-89 score, experiencing a 
generalized tonic-clonic seizure ever, ethnicity, driving status, marital status, employment status, 
epilepsy foundation of America Concerns Index (EFA) score, and the social support and social 
isolation subscale scores measured on the QOLIE-89 at baseline.  
 
First, any possible association between each independent variable was explored in univariate 
analysis; for two quantitative variables a chi-squared test was used, while a t-test for differences 
between means was used for continuous variables. Finally, to estimate the effect of each 
independent variable on the depression remission, logistic regression models were run. The 
dichotomous variable in the logistic regression model is MDD active or in remission at sixteen 
weeks (based on the MINI score).  All the hypotheses were rejected at an alpha level of .05.  
 
Results: 
A total of 140 participants were enrolled and randomly assigned to either the sertraline or CBT 
treatment groups.  At enrollment the mean age of the cohort was 39 years, seventy-seven 
subjects were women.  No differences were found between treatment groups with respect to 
baseline number of seizure medications, BDI scores, CES-D scores, AEP scores, or QOLIE-89 
scores. As a comparative effectiveness trial, the protocol allowed follow up after stopping 
assigned treatment, so that 117 (83.6%) participants completed assessments at week 16.  
 
Of the 117 subjects that completed the final assessment, the mean BDI scores at baseline and 
week 16 for the sertraline group (n=59) were 24.2 (s.d 8.4) and 12.3 (s.d. 9.9), and for the CBT 
group (n=58) were 26.9 (s.d. 10.5) and 12.8 (s.d. 11.9). Of the 96 subjects that completed the 
MINI at week 16, 38 of the 48 (79.2%; 95%CI±11.5) in the sertraline group and 41 of 48 
(85.4%; 95% CI±10.0) in the CBT group were in remission from major depression (between 
group chi-square=0.64; p =0.42).For a detailed description of the original patient group, see the 
original study (Guilliam FG).  
The the primary univariate analysis showed that the baseline CES-D (p-value< .0001), and 
ethnicity (p-value<.00001 ) were statistically significant variables (Tables 1&2)  
 
We included in the logistic regression the variables that were found to be statistically significant 
on univariate analysis. The logistic regression model showed that the baseline severity of 
depression based on the CES-D score was a significant clinical predictor of response to 
depression treatment in Epilepsy persons (p< .035 with a OR 1.062)  (Table 3). The more severe 
the MDD was at baseline, the higher the CES-D, the less likely the patient with Epilepsy was to 




Education Years (Mean) 14.37 13.96 0.50
Age (Mean) 40.68 37.08 0.17
CES-D (Mean) 29.09 36.71 0.00*
QOLIE-89 (Mean) 56.12 57.71 0.70
EFA (Mean) 58.70 66.21 0.07
Table 1: Relationship of continuous 
variables at baseline and MDD Remission 
based on the MINI score at 16 weeks






In this study we aimed to evaluate the predictive variables to depression treatment that can be 
obtained in clinical evaluation of persons with Epilepsy. The ethnicity variable, while significant 
in the univariate analysis was not significant in the logistic regression. Only four of the patients 
were of Hispanic or Latino origin, so these results cannot be representative of the population. A 
more representative population of a Hispanic population should be further studied. A further 
analysis of variables in each treatment group (Sertraline vs CBT) could yield more specific 
data.   
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